Altium Capital Management’s Coherus Oncology CHRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-136,623
Closed -$2M 137
2021
Q1
$2M Sell
136,623
-80,302
-37% -$1.36M 0.55% 76
2020
Q4
$3.77M Buy
+216,925
New +$3.86M 1.41% 26

Other funds holding CHRS

Altium Capital Management's CHRS Position: Q2 2021 in Review

Altium Capital Management sold out of Coherus Oncology (CHRS) in Q2 2021, closing a stake of 136,623 shares — an estimated $2M sold.

Altium Capital Management first reported a position in CHRS in Q4 2020 and held it in 2 quarters. The position peaked at $3.77M in Q4 2020. 188 funds tracked by Wall St. Rank hold CHRS as of Q2 2021.

  • Altium Capital Management reported no remaining Coherus Oncology position as of Q2 2021 after selling out during the quarter.
  • Altium Capital Management sold 136,623 Coherus Oncology shares in Q2 2021, an estimated $2M.
  • Altium Capital Management first reported a position in Coherus Oncology in Q4 2020 and held it in 2 quarters.
  • Altium Capital Management's Coherus Oncology position peaked at $3.77M in Q4 2020.
  • 188 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2021.

Based on Altium Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.